EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis

Joseph Azuri iD, Ariel Hammerman iD, Enis Aboalhasan iD, Ben Sluckis, Ronen Arbel

Obesity · 2023

DOI: 10.1002/oby.23752 ↗

At a glance

Journal article in Obesity, 2023. Written by Joseph Azuri and 4 co-authors. Institution: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Major MEDLINE topics: Liraglutide, Diabetes Mellitus, Type 2. Cited 21 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

Higher doses of the glucagon‐like peptide‐1 agonists liraglutide and, more recently, semaglutide have demonstrated a significant reduction in body weight. However, their comparative value for money for this indication is unclear.

Methods

The cost needed to treat to achieve a 1% reduction in body weight using semaglutide or liraglutide was calculated. The body weight reductions were extracted from the published STEP 1 trial and the SCALE trial results, respectively. A scenario analysis was performed to mitigate the primary differences between the two studies' populations. Drug costs were based on US GoodRx prices as of October 2022.

Results

Liraglutide in STEP 1 resulted in a weight loss of 5.4% (95% CI: 5%‐5.8%). Semaglutide in SCALE resulted in a weight loss of 12.4% (95% CI: 11.5%‐13.4%). The total cost of therapy with liraglutide during the trial was estimated at $17,585 compared with $22,878 with semaglutide. Accordingly, the cost needed to treat per 1% of body weight reduction with liraglutide is estimated at $3256 (95% CI: $3032‐$3517) compared with $1845 (95% CI: $1707‐$1989) with semaglutide.

Conclusions

Semaglutide provides significantly better value for money than liraglutide for weight reduction.

Subjects

MeSH terms (MEDLINE)

LiraglutideDiabetes Mellitus, Type 2HumansHypoglycemic AgentsGlycated HemoglobinWeight LossBody WeightSemaglutide

Substances

LiraglutideHypoglycemic AgentsGlycated HemoglobinSemaglutide

Authors and institutions

  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Maccabi Healthcare Services, Tel Aviv, Israel.
  • Clalit Health Services, Tel Aviv, Israel.
  • Maximizing Health Outcomes Research Lab, Sapir College, Israel.
  • Meuhedet Health Services, Jerusalem, Israel.

ORCID profiles: Joseph Azuri, Ariel Hammerman, Enis Aboalhasan

Cite

APA

Azuri, J., Hammerman, A., Aboalhasan, E., Sluckis, B., & Arbel, R. (2023). Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis. Obesity. https://doi.org/10.1002/oby.23752

Vancouver

Azuri J, Hammerman A, Aboalhasan E, Sluckis B, Arbel R. Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis. Obesity. 2023. doi:10.1002/oby.23752

BibTeX
@article{Azuri2023,
  author = {Azuri, Joseph and Hammerman, Ariel and Aboalhasan, Enis and Sluckis, Ben and Arbel, Ronen},
  title = {Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis},
  journal = {Obesity},
  year = {2023},
  doi = {10.1002/oby.23752}
}
Start for free →